All 1 tracked stories fall under one category: earnings. REGENXBIO Inc. is most often covered alongside BioLargo, Inc., which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 5 original sources each against 2.5 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about REGENXBIO Inc.
All 1 tracked stories fall under one category: earnings. REGENXBIO Inc. is most often covered alongside BioLargo, Inc., which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 5 original sources each against 2.5 for the same window. Their average consequence score of 5 runs below the beat's 6.6 for that window. We currently track 1 Finance story that mention REGENXBIO Inc., all published on March 9, 2026.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 92 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering REGENXBIO Inc.. Shared-story counts are live from our verified record — not editorial picks.
A series of Q4 2025 earnings reports from emerging technology and biotech firms reveal significant bottom-line misses, led by a substantial shortfall from long-duration energy storage provider ESS Tech. The results underscore the ongoing challenges for growth-stage companies in balancing heavy R&D investment with path-to-profitability expectations.
REGENXBIO Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.